MSI_1318 by Della Malva, Antonio et al.
  
MSI_1318 
 
Basic science as a prescription for 
breakthrough inventions in the 
pharmaceutical industry 
Antonio Della Malva, Bart Leten, Stijn Kelchtermans and 
Reinhilde Veugelers 
 
      
      
 
 
 
      
 
 1 
 
Basic Science as a Prescription for Breakthrough Inventions in the 
Pharmaceutical Industry* 
 
Antonio Della Malva1, Bart Leten1,2, Stijn Kelchtermans1,3, Reinhilde Veugelers1,4 
 
1 Department of Managerial Economics, Strategy and Innovation, University of Leuven,  
Naamsestraat 69, B-3000 Leuven, Belgium  
2 Vlerick Business School (Belgium) 
3 Hogeschool-Universiteit Brussel (Belgium) 
4 ECOOM (Leuven), Bruegel (Brussels), CEPR (London) 
 
September 2013 –  
Do not cite without permission  
 
This analysis contributes to the understanding of the role of basic science in generating breakthrough inventions 
(BTs) in the pharmaceutical industry.  Recognizing the within-firm heterogeneity of inventive activities, we look not 
only at the firm level, but also at the firm-technology level for characteristics determining breakthroughs. A key 
finding is that firms pursuing basic science are more likely to produce breakthrough inventions. At the same time, 
doing more basic science in science disciplines that are closely linked to a given technology domain does not 
increase the likelihood of BTs in that particular technology. The insignificance of basic science intensity at the 
technology level,  coupled to the significance at the firm level, suggests that the breakthrough rewards from 
science capacity are not reaped in the technology areas immediately involved in basic science,  but in other areas 
of the technology portfolio of the firm. Our findings are consistent with the view of science as a map to span 
processes of local search and the wider applicability of scientific insights. 
 
 
Keywords: breakthrough invention, pharmaceutical industry, basic science  
 
* We thank seminar participants at the Competition and Innovation Summer School 2012, in particular Adam Jaffe 
and Francesco Lissoni, participants at the EuSPRI Roundtable on “Organizing Radical Innovation”, and participants 
at the T2S conference 2013, New York for helpful comments. Data on scientific production was kindly provided by 
Bart Thijs at ECOOM – KULeuven.  Financial support from the European Union (PIEP-2011-302034), KULeuven  
(GOA/12/003) and FWO Flanders (G.0825.12) is gratefully acknowledged.    
 2 
 
1. Introduction 
Since Schumpeter’s seminal contributions (1939), economists have debated on the 
implications of different typologies of inventions. Inventions range from run-off-the-mill or 
incremental inventions to breakthrough or radical inventions. Whereas most of the measured 
productivity growth might come from incremental inventions (Baumol, 2004), breakthrough 
inventions, although more “rare events”, introduce new concepts that have the potential to 
generate new markets and - through a mix of competitive and cooperative interactions - trigger 
follow-up inventions and growth in other firms. They are therefore critical building blocks of 
nations’ creative destruction capacity and their long-term economic growth (Nelson & Winter, 
1982; Malerba, 2004). 
The debate on breakthroughs and their importance for corporate and country growth 
has remained rather rhetorical, only scantly backed up by empirical evidence. The lack of good 
empirical evidence is partly caused by a vague definition of the main concept and a lack of large 
scale empirical identification of breakthrough inventions moving beyond small numbers of case 
studies or self-reported measures (Henderson, 1993; Christensen, 1997; Schneider and 
Veugelers, 2010). 
This paper contributes to a better understanding of the antecedents of breakthrough 
inventions, which are defined as those inventions with a high impact on subsequent inventive 
activity 1 . The few empirical studies on breakthrough inventions have looked at the 
characteristics of the individual invention (e.g. Schoenmakers & Duysters, 2010; Arts & 
                                                          
1  As breakthrough inventions do not necessarily make it into commercial breakthroughs, our analysis cannot be 
extended into determinants of commercial breakthroughs. For an analysis of commercial breakthroughs in the 
Pharmaceutical industry,  see a.o.  Cockburn (2007). 
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Veugelers, 2012), firm  characteristics (e.g. Ahuja and Lampert, 2001) or inventor characteristics 
(e.g. Singh and Fleming, 2010) most conducive to breakthroughs. Recognizing the within-firm 
heterogeneity of inventive activities, this study looks at the firm-technology level for 
characteristics determining breakthroughs. This research set-up allows a more comprehensive 
approach than most prior work by analysing simultaneously firm characteristics and firm-
technology characteristics which are more prone to lead to breakthrough inventions.  
In our quest for antecedents, we are particularly interested in the link to basic science as 
a predictor of high impact inventions. We examine science involvement both at the level of the 
firm and the level of the specific technology. This allows us to check “where” the benefits of 
basic science are realized. We do this for a large sample of firms in the pharmaceutical industry. 
We focus on this industry for two reasons. Firstly, innovation in the pharmaceutical industry is 
characterized by a high failure rate and large (mainly development) costs. This creates pressure 
to identify management practices that boost breakthrough diagnostics and therapeutics 
(Munos & Chin, 2011).  Secondly, basic science is an important source for innovation in the 
pharmacetucail industry (Narin and Olivastro, 1992; Narin et al., 1997), with science insights 
resulting in the discovery of many breakthrough drugs (Cockburn and Henderson, 1998). The 
link between basic science and drug discovery has even increased over time, with companies 
moving from a mere “random screening” of compounds towards “informed” discovery 
methods fuelled by scientific knowledge (Pisano, 1997; Lim, 2004). While basic science is part 
of the drug discovery process of most firms, there is significant heterogeneity across firms in the 
basic science strategies adopted (Gambardella, 1995; Belderbos et al., 2010), providing room for 
further analysis of how basic science involvement may affect the breakthrough character of 
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inventive activities of firms. Taking into account that innovation in the pharmaceutical industry 
is carried out by dedicated biotech firms (DBFs) and large diversified pharmaceutical firms 
(LDPFs), who differ substantially in the way they tackle the innovation challenge, we also 
compare what determinants favor breakthrough inventions for each type of firm.  
We characterize breakthroughs with varying intensities of impact distinguishing 
between inventions with an increasingly large footprint on subsequent inventive activity. To 
identify high-impact inventions, we look at the high end of the impact distribution, using 
benchmarks that are technology-specific i.e. our importance classification acknowledges that it 
is harder to ‘stand out’ in some technology domains than in others. Previously used measures 
tend to define high-impact inventions as those in a given top percentile or above a fixed cut-off 
value of the impact distribution without accounting for the variability of the entire distribution 
(Ahuja & Lampert, 2001; Singh & Fleming, 2010; Schoenmakers & Duysters, 2011; Kerr, 2010). 
We find that firms pursuing basic science are more likely to generate breakthrough 
inventions. Interestingly, breakthrough inventions are not associated to higher scientific efforts 
targeted to the focal technology. The result – importance of scientific efforts at the firm level, 
but insignificance of targeted scientific efforts within the firm indicates that the breakthrough 
rewards of basic science are not reaped within technologies that are immediately involved in 
basic science, but in other technologies in a firm’s portfolio. Our findings are consistent with a 
view of science as map (Fleming and Sorenson, 2004) which helps spanning the boundaries of a 
process of local search (Rosenkopf and Nekar, 2001), and show that scientific insights often 
have practical value in many different technologies. With respect to other BT-determinants, we 
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find that firms produce more breakthroughs in technologies in which they have 
disproportionately focused their technology portfolio and achieved technology leadership. 
Ceteris paribus, DBFs are more likely to generate breakthroughs than LDPFs. 
The paper will first illustrate some previous findings from the literature on breakthrough 
inventions and pay special attention to two neglected dimensions: the within-firm 
heterogeneity across technologies and the role of basic science. We will present the data and 
detail the construction of the variables used in this study. The results will precede some 
concluding remarks. 
2. Antecedents for Breakthrough Inventions 
The most recent literature on breakthrough inventions defines them as foundational inventions 
that provide the framework for many subsequent inventions,  contributing disproportionally to 
future technological developments (Rosenberg, 1994, Fleming 2001). Consistent with this 
definition,  patent statistics can identify those inventions which are overly cited by later 
inventions. The empirical literature using highly cited patents to identify breakthroughs have 
mostly looked at the origins of these inventions.  Although breakthroughs are often casted as 
revolutionary new ideas, they are often found to be much more evolutionary in origin,  
recombining already existing pieces of technological know-how. 
New and small firms are considered to be at an advantageous position to generate 
breakthroughs.  Older and larger firms, having to surmount an incumbency trap, are typically 
taken to be disadvantaged in introducing BTs. Breakthrough inventions render the capabilities 
of existing firms obsolete, putting them at a relative unfavourable position compared to follow-
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up inventions on existing inventions in which they excel (Henderson, 1993; Shane, 2001).  
Empirical evidence supports that young innovative firms are more likely to introduce radical 
innovations (e.g. Schneider & Veugelers, 2010).  But large firms are not necessarily doomed to 
incremental improvements of well-established technologies (Ahuja and Lampert, 2001; Chandy 
& Tellis, 2000), particularly if they can recombine existing competences with unfamiliar 
components into new applications (e.g. Fleming, 2001; Arts, 2012).   
In one of the first quantitative firm-level studies on the topic, Ahuja and Lampert (2001) 
argue, among other things, that large firms can overcome innovative traps by experimenting 
with technologies which are either new to the firm or new to the technological domain.  
Fleming (2001) zooms in on this experimentation.  He demonstrates that breakthroughs often 
originate from new re-combinations of the most familiar technological components, i.e. 
components which have been used extensively in the past but in different combinations.  Green 
and Schilling (2011) analyse how different features of the search process underlying extreme 
impact ideas, namely search depth (the extensiveness of search within a particular domain), 
search scope (the breath of a search across domains), and atypical connections, affect the 
likelihood of breakthrough idea generation. The authors stress the positive implications of deep 
reservoirs of knowledge in particular domains and the interaction of the latter with an 
extensive search breath for impactful ideas to emerge. Agents should possess extensive 
knowledge of the domains in which critical solutions are sought and concurrently should extend 
the search to other domains. This finding is in line with a view of learning which pays off its 
highest dividend when it is directed beyond the actual technological and organizational 
boundaries (Rosenkopf and Nerkar, 2001) and geared towards related familiar domains 
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(Schilling et al., 2003). In line with this view, Phene et al. (2006) have highlighted the 
importance of related technical solutions in the case of biotechnology, noting however that too 
much exploration, spanning both technological and spatial boundaries at the same time, could 
turn harmful for the generation of breakthrough ideas.  
Taken together, these findings from the literature suggest that the overall technology 
size, scope and specialisation pattern of firms will matter for generating breakthrough 
inventions.  More particularly, they suggest within-firm heterogeneity across technologies with 
respect to the likelihood of breakthroughs. Firms might have different abilities to generate 
impactful inventions in technology domains, according to their relative strength in the diverse 
range of domains in which they operate and which they can leverage into other domains.   
 
Basic Science and Breakthrough Inventions 
According to the National Science Foundation (NSF) basic science is defined as the 
systematic study directed towards greater knowledge or understanding of the fundamental 
aspects of phenomena and observable facts without specific immediate commercial 
applications in mind (NSF, 2009). Corporate level basic science activities are concentrated in a 
small number of science-intensive industries, most prominently pharmaceuticals, electronics 
and aerospace (Mansfield, 1980; Rosenberg, 1990). Applied to the pharmaceutical industry, 
basic science includes attempts to reveal the mechanisms and processes of diseases, but does 
not include applied research activities such as compound screening, clinical trials and dosage 
testing (Lim, 2004).  
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Science should matter for the generation of breakthrough inventions which most likely 
do not reside within the boundaries of the current paradigm and might entail a new 
recombination or shift in trajectory.  Science entails a process of learning that generates 
knowledge on which firms can draw for their search into new territories.  
Own science capabilities act as an admission ticket to R&D partnerships with university 
scientists and their networks (Liebeskind et al., 1996; Cockburn and Henderson, 1998; Murray, 
2004). In order to plug in science networks, firms must have scientific competences to 
demonstrate their value as R&D partners (Hicks, 1994).  Own scientific capabilities lead to a 
better identification, absorption and integration of external (public) knowledge (Cohen and 
Levinthal, 1990;  Rosenberg, 1990; Gambardella, 1995; Cassiman and Veugelers, 2006).  A firm’s 
scientific capability serves as a map for technological landscapes guiding applied research in the 
direction of most promising technological avenues avoiding thereby wasteful experimentation 
(Rosenberg, 1990; Fleming and Sorenson, 2004). A better and more fundamental understanding 
of the technology landscape encourages non-local search for improving technologies as 
opposed to local search, leading to more diverse research trajectories being explored with 
higher potential pay-offs. Not only the average quality of the technologies is likely to be 
affected (Fabrizio, 2009): scientific capabilities might also affect the distribution of outcomes. 
Firms with scientific capabilities can be expected to generate more “unexpected” outcomes, 
leading to a higher probability of breakthrough inventions (Sobrero and Roberts, 2001).   
Although the literature offers a basic understanding of the process through which 
breakthroughs emerge and the role of science, no insights are provided on “where” 
breakthroughs are generated within the firm. Do breakthroughs happen in technology fields 
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that are closely linked to the science fields where basic science is conducted, or do they 
manifest in other technologies in firms’ portfolios Basic scientific research into disease 
mechanisms may lead to diagnostic or therapeutic insights with a broad scope of applications. 
More specifically, by looking beyond the immediate challenges posed by a given technology, 
basic science helps building a more comprehensive mental map of the problem at hand and 
may therefore be expected to contribute to fundamentally new approaches. This “reframing” 
function of basic science  may lead to high-impact inventions outside the technology domains 
that have hitherto been linked to particular scientific disciplines. For example, while scientific 
advances in virology may traditionally have led to new vaccines (e.g. IPC class A61K), they have 
increasingly  found applications in genetic engineering (e.g. IPC class C12N). In fact, the whole 
biotech (r)evolution is in itself a demonstration of this reframing principle. Based on these 
arguments, one could expect that the breakthrough rewards of basic science are realized within 
firms to a large extent in other technology fields that those that are immediately involved in the 
basic science. 
3. Research design  
3.1. Sample 
To examine the relationship between basic science and breakthroughs, we use a panel 
of firms in the pharmaceutical industry. The sample firms are selected as the highest R&D 
spenders in the pharmaceutical industry based on the ‘2004 EU Industrial R&D Investment 
Scoreboard’. This ranking lists the top 500 corporate investors in R&D whose parent is located 
in the EU, and the top 500 companies whose parent is located outside the EU (mainly US and 
Japan), based on corporate R&D expenditures in 2003.  We match these firms with patent 
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information from the European Patent Office (EPO).  After excluding companies that specialize 
in medical instruments, we are left with 136 dedicated biotech firms (DBFs) and large 
diversified pharmaceutical firms (LDPFs) which applied for EPO patents between 1996 and 
2002.2 This selection criterion retains in the sample the biotechnology firms who have played a 
key role in drug discovery in the past three decades (Danzon et al., 2005). The presence of 
these two types of firms enriches the data since, unlike the large Pharma firms, the small and 
entrepreneurial biotech firms often have their roots in public research and rely on markets for 
technology to commercialize their inventions rather than bringing new drugs to market 
themselves, except for the few large fully integrated biotech companies (FIBCOs).3  
Patent data are used to measure the inventive activities of the sample firms. Patents are 
a good indicator of inventions in the pharmaceutical industry since the propensity to patent 
inventions is amongst the highest of all industries (Arundel and Kabla, 1998; Campbell, 2005). 
We rely on patent data from the European Patent Office (EPO). European patent data are 
preferred to the more commonly used data from the United States Patent and Trademark 
Office (USPTO). EPO patents are, typically, considered to provide a better indication of valuable 
inventions: the cost of patenting is two to five times higher at EPO; the workload of patent 
examiners is four times smaller at EPO; and the EPO has a 20-30% lower granting rate than the 
USPTO (Van Pottelsberghe de la Potterie & François, 2006; Quillen & Webster, 2001; Jaffe & 
Lerner, 2004). Since company names in patent databases are not harmonized and patents may 
be applied for under names of subsidiaries or divisions of a parent firm, we collected patent 
                                                          
2 The original database contains information on patenting activity of the sampled firms as of 1995. The first year is 
used to construct some of the control variables used in this study.   
3 For a more elaborate discussion of the ‘disintegration’ trend in the pharmaceutical industry, see Cockburn (2007). 
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data at the consolidated parent firm level. Therefore, we searched, for each parent firm, for 
patents under the name of the parent firm as well as all their majority-owned subsidiaries. For 
this purpose, yearly lists of companies’ subsidiaries included in corporate annual reports, yearly 
10-K reports filed with the SEC in the US, and, for Japanese firms, information on foreign 
subsidiaries published by Toyo Keizai in the yearly ‘Directories of Japanese Overseas 
Investments’, were used. The consolidation was conducted on a yearly basis to take into 
account changes in the group structure of sample firms due to acquisitions, mergers, green-
field investments and spin-offs. Acquisitions, and their patent stocks, are considered part of a 
parent firm from the year the acquisition transaction has been completed.  
We restrict the analysis to those technologies where firms in our sample cover at least 
1% of the patent applications at EPO. This restriction ensures that minor and unrelated 
technologies are excluded from the analysis. The 136 firms in the final sample account for 
30,083 patent applications at the EPO in the observed 8-year period4. Our sample is composed 
of 77 DBFs and 59 LDPFs. 46% of our firm-technology-year observations are from DBFs - and 
almost 26% from firms with less than 250 employees.  Most of the sample companies are based 
in the EU (61 out 136), 55 companies are US-based, 19 are from Japan and 1 firm is from Israel. 
Table A.1 reports the list of firms used in our sample, their geographical origins and the 
typology.  It includes both the largest among Pharma companies, such as Merck & Co. and 
                                                          
4 The patent applications considered in the analysis have memberships in 108 3-digit IPC patent classes (out of 129 
3-digit IPC classes). With the 1% coverage restriction,  83 technology classes are excluded.   
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Pfizer, next to large Biotech firms,  such as Amgen,  as well as small companies with few 
patents,  most often in Biotech5.     
3.2. Identifying Breakthrough Inventions 
In line with earlier research, we use patent-based indicators for identifying inventions 
that are breakthroughs (e.g. Ahuja & Lampert, 2001; Singh & Fleming, 2010).6 Patents are 
widely used for invention analysis since they provide standardized information, suited for large 
scale analysis across time, country, technology and organisations. Patents are especially 
interesting for analysing breakthrough inventions and their antecedents since they leave a 
publicly accessible trail of backward and forward citations. These citations allow tracing, 
respectively, the inventions’ origins and their technological impact on subsequent inventive 
activity.  
Drawing the line between moderately influential inventions and ‘extremely influential’ 
or breakthrough inventions is not straightforward however. Breakthrough inventions have a 
disproportionate impact on future technological developments, but are rare events (Kuznets, 
1962, as in Trajtenberg et al., 1997). Prior studies have identified breakthroughs as the top 1, 5 
or 10 centiles of the forward citation distribution (Ahuja & Lampert, 2001; Singh & Fleming, 
2010; Kerr, 2010) or those exceeding a fixed cut-off value of number of forward citations 
                                                          
5 The share of generic firms is negligible, around 1% of the sample; they are not found to produce any 
breakthrough inventions, according to the definition of section 3.2. We therefore exclude this dimension from the 
analysis. 
6 As an alternative to patent-citations, some scholars (e.g. Fontana et al., 2012) used data on R&D awards to 
identify breakthrough inventions. Comparing the number of patents received by award winning inventions and a 
control group, Carpenter et al. (1981) found that award winning inventions receive significantly more citations. 
This shows the close correspondence between citations and data on R&D awards to identify breakthrough 
inventions. 
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received (Schoenmakers and Duysters, 2011). A downside of these approaches is that they do 
not consider the variability of the entire forward citation distribution. In particular, for a given 
technology the forward citations may be rather evenly distributed over patents and hence the 
impact of “top centile inventions” may not be substantially higher than the impact of 
“moderately impactful” inventions.  
In order to trace the inventions that truly stand out in a given technology domain in 
terms of impact, we take into account the dispersion of the forward citations around the mean 
for each 3-digit IPC patent class. For the purpose, we used the November 2011 version of the 
EPO/OECD Citation Database, which covers all patent applications (and their reference) at EPO 
since its foundation (Webb et al., 2005). More specifically, we calculate the number of forward 
citations received by the focal patent in the first 5 years after application from other patent 
applications at EPO, and define a breakthrough as a patent having a number of citations that is 
at least a number of standard deviations above the mean, for at least one 3-digit IPC patent 
class to which the patent belongs. As the reference scenario, we will be using 3 standard 
deviations,  but to study the intensity of the breakthrough character of the invention,  we will 
also look at 4 and 5 standard deviations for more extreme breakthroughs.  While the standard 
deviation takes into account the dispersion of forward citations in the technology class, the 
mean controls for the importance of the technology class as such and for the propensity to 
patent in that particular technology7.  
                                                          
7 Although there is not a clear rule for defining BTs, we would like to highlight the extent to which our approach 
differs from other approaches, such as the “top 1%” criterion”, where the threshold is defined as the top 1st centile 
in the distribution of forward citations, in identifying BTs. For the most relevant technologies of the analysis, for 
instance, patent class A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE), C12 (BIOCHEMISTRY) and G01 
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Using patent citation information to measure impact restricts the analysis to assessing 
breakthroughs in the technological dimension (Henderson et al., 1998; Jaffe et al., 2000). As 
technological breakthroughs do not necessarily make it into commercial breakthroughs,  our 
analysis cannot be extended into determinants of commercial breakthroughs8. Nevertheless 
previous research has indicated that forward citation patterns are related to social value 
(Trajtenberg, 1990) and private value (Harhoff et al, 1999; Hall et al., 2005; Gambardella et al., 
2008).  
3.3  Scientific Involvement of Firms 
We look at measures to capture the involvement in science, both at firm-level and at 
firm-technology level.  The simultaneous use of both measures allows us to examine whether 
the breakthrough rewards of science materialize in technologies that are directly linked to the 
scientific research, or in other technologies of the firm. We consider active involvement in 
science through the number of scientific publications authored by researchers employed by the 
focal firm. To construct the science variables, we first extracted all publications in the Science 
Citation Index database of ISI/Thomson Scientific. Publication data is collected at the 
consolidated parent firm level, following a similar approach as the one followed for the 
collection of patent data. We used the CHI journal classification to identify publications on 
‘basic research’. The CHI journal classification assigns each of the SCI journals in one of four 
                                                                                                                                                                                           
(MEASURING, TESTING), the patents in the top 1% in each class receive less citations than our benchmark 
definition for BTs, mean plus 3 standard deviation. These are 3 out of 7 cases in which the top 1% of patent 
applications in a given patent class receive less citations than our benchmark definition. For the remaining 115 
patent classes, our benchmark definition of BTs would be more inclusive than the “top 1%” criterion. Finally, for 34 
patent classes, instead, our benchmark definition of BTs, is more inclusive than the defining a threshold at the 5th 
top centile of the distribution of forward citations.  
9 Our results are robust to adding a control for the applied science activities of firms (publications in levels 1-3). 
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research levels, from very applied, targeted research to basic research. Biomedical journals are 
classified as ‘clinical observation’ (level 1), ‘clinical mix’ (level 2), ‘clinical investigation’ (level 3) 
and ‘basic biomedical research’ (level 4). Journals that are classified in level 4 are considered as 
reporting basic research findings.  As we are interested in scientific capabilities,  we will only 
consider the publications classified in level 4.  Our firms file on average for 220 SCI publications 
per year. About 35% of the SCI publications of the sample firms are published in basic research 
journals and are used in the construction of the science variables. 9 
To calculate the specialization of scientific activities of our firms in technology classes,  
we matched the publications to 3-digit IPC technology classes through a concordance table 
between scientific disciplines10 () and IPC classes that is created by Van Looy et al. (2004, 2006). 
The science-technology (ST) concordance is based on scientific references (almost 500’000)  in 
granted EPO and USPTO patents  applied between 1996 and 2001. Surveys of patent inventors 
(Tijssen, 2001; Fleming and Sorenson, 2004) have shown that patent inventors are aware of a 
significant share of the scientific papers cited in their patents, qualifying scientific non-patent 
references as indicators of the role of science in technology research, especially at an 
aggregated level such as technologies (Branstetter & Kwon, 2004; Fleming and Sorenson, 2004, 
Van Looy et al. 2007). 
 The ST concordance relates ISI science fields to 3-digit IPC technology classes via a set of 
probabilities. A high probability reflects that a science field is frequently cited in a particular 
                                                          
9 Our results are robust to adding a control for the applied science activities of firms (publications in levels 1-3). 
10 Journal issues (and the articles they contain) are classified into one of 222 ISI Subject Categories. To increase the 
robustness of the concordance, the Expertise Centre for R&D Monitoring (ECOOM, KU Leuven) aggregated these 
detailed categories into 68 scientific disciplines.  
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technology domain. The probability linking science field i and technology field j is calculated as 
the ratio of “the number of scientific citations from patents in technology j to publications in 
science domain i” and the “total number of citations to publications in science field i across all 
technology fields”.11 An example of a science field that is frequently cited in patents is 
immunology. This field receives most citations (>85 percent) from three IPC3 classes: A61 
(medical and veterinary technologies), C07 (organic chemistry), C12 (biochemistry)..12  
Having identified basic research publications of the firms in our sample and having 
assigned them to technology classes to which they are mostly related, we measure the science 
intensity at the firm-level the scientific publications in basic research authored by corporate 
scientists in the four years preceding the focal year per patent application in the previous four 
years (Firm Science Intensity). Publication variables are computed as four-year stocks to make 
the variables less prone to small number problems due to small numbers of annual publications 
for some sample firms. Looking at the publications as a ratio relative to the number of patents,  
eliminates the scale dimension when examining the science impact.  To examine whether 
scientific capacity would matter not just at the aggregate firm level,  but also at the specific 
focal technology level,  we include the number of a firm’s scientific publications related to the 
focal technology (using the concordance table, as explained above) relative to the number of 
firm patents in the technology between t-4 and t-1 (Tech Science Intensity). Whereas the first 
measure captures the overall involvement of the focal firm in basic science, the second 
                                                          
11 We have multiplied these probabilities by the overall technology intensiveness of science fields (i.e. the average 
number of times that publications in the field are cited in patents). We have also conducted analyses whereby we 
didn’t apply this correction to the Tech Science Intensity variable; this analysis gives very similar results. 
12 See Van Looy et al. (2004, 2006) for more details on the methodology to construct the ST concordance. 
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measure provides an indication of how focused are the scientific capabilities of the focal firm to 
a specific technology area. 
3.4 Firm and Firm-Technology Controls 
We control for the technological size of the parent firm (Firm Technology Size), 
measured as the logarithm of the number of patent applications.13 It is usually highly correlated 
with firms’ age, and aims at controlling for scale effects – i.e. scale economies, scope 
economies, etc.  We also control for firms with less than 250 employees (SME). 
To further characterize technology depth and breadth positions of firms, we need to 
determine how relevant is the inventive contribution of a particular firm for a technology and 
how central is the latter in the technological portfolio of a firm. We measure the leadership of a 
firm in a technology with respect to other competitors in the sample as the share of patent 
applications at the EPO by the focal firm in the focal technology class (Tech Lead). We also 
characterize the centrality which the focal technology has in the portfolio of the focal company 
as the number of patent applications in the focal technology divided by the total number of 
patent applications by the focal firm (Tech Specialization). We also include a measure for the 
level of technology diversification in a firm’s technology portfolio. Unlike the previous two 
measures, which are firm-technology specific, the latter is a firm-level one and synthesizes the 
extent to which firms marshal different technologies in their inventive process. Firms with a 
more diversified technology portfolio have access to a broader set of knowledge components to 
                                                          
13 A disadvantage of the use of patents as indicator of the scale of firms’ inventive activities is that patents are an 
output indicator, which do not only reflect differences in inputs, but are also affected by patent propensities. 
However the propensity to patent is high in the pharmaceutical industry (Arundel and Kabla, 1998), making R&D 
expenditures and patent counts close substitutes for the scale of inventive activities in this particular industry. 
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combine and create new inventions with potentially higher impact (Fleming, 2001). The variable 
is calculated as the Herfindahl index of the shares of the 3-digit IPC technology classes in the 
focal firm’s patent portfolio (Tech Concentration). All the patent variables are 1-year lagged. 
Finally, we control for differences related to the two main types of firms in the 
pharmaceutical industry. Dedicated biotech firms (DBFs) tend to differ systematically from the 
large diversified pharmaceutical (LDPFs) companies in the sense that they are created on the 
basis of their distinctive competencies in biotechnology, tend to have their roots in public 
research, rely on markets for technology rather than bringing new drugs to market themselves, 
and have fewer products in the market place to cannibalize (Orsenigo, 1989; Cockburn, 2007). 
We identify DBFs with a dummy variable (Biotech). We also control for whether the parent firm 
is headquartered in the United States of America (US), checking whether US firms have a 
competitive edge over non-US firms, being at home in the most important market for 
pharmaceuticals.14  Table 1 reports a description of the variables used in the study. 
4. Descriptive Statistics  
Table 2 reports the summary statistics on breakthroughs in our sample.   Almost 5 out of 
15 patents (the average size of the yearly technology-specific patent portfolio of a firm) do not 
receive any patent citation, being about 32% of the patents. About the same share of 
inventions receive more citations in the first five years from application at EPO than the 
average patent in the technology (Above Average). Breakthrough inventions are rare events,  
the more so,  the more strict our definition for BTs.  While on average 3% of the firms’ yearly 
                                                          
14 In 2011, North America accounted for 41.8% of world pharmaceutical sales compared with 26.8% for Europe 
(Efpia, 2012). 
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patents in a technology class are BT with the 3SD criterion,  only 1% classify as BT with the 5SD 
criterion. .    
[INSERT TABLE 2 ABOUT HERE] 
The mean number of breakthroughs is smaller in the biotech subsample than for the 
large pharmaceutical firms, which is not surprising since biotech firms are on average smaller in 
technology size, cf. infra.  The absolute disadvantage of biotech becomes however smaller the 
more extreme the breakthroughs are.  Moreover, in relative terms (breakthroughs as a share of 
overall patenting activity, also shown in Table 2), DBFs do not seem less apt to create 
breakthroughs than LDPFs, if not more apt.        
[INSERT TABLE 3 ABOUT HERE] 
Table 3 reports the summary statistics on our independent variables. On average, the 
firms in our sample have applied yearly for almost 52 patents (Firm Tech Size, exp. (3.949)) at 
EPO between 1995 and 2002. The firms account on average for 0.3% of patent applications at 
the EPO in the technologies in which they operate (Tech Lead). Corporate scientists have 
published on average 1.4basic science articles in the previous four years for every patent; 
despite producing in total less scientific articles than LDPFs, DBFs produce relatively more 
articles than patents: there are almost 3 articles for every 2 patent applications in the case of 
DBFs versus about 1 paper per patent in the case of LDPFs.   Tech science intensity takes an 
average value of 1.6, and is significantly higher for LDPFs than DBFs. 
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The last column of Table 3 indicates that LDPFs dominate DBFs in terms of technology 
size and every covariate which is size dependent, which is why we scale other covariates where 
needed.  Biotech firms are overrepresented among the SMEs and US firms in the sample. DBFs 
concentrate their inventive activities in a more pronounced manner relative to LDPFs: on 
average DBFs have a significantly higher share of their overall patenting activity in a specific 
technology class (Tech Specialization) than LDPFs.  Their distribution over technology classes is 
however more balanced than it is for the LDPFs: Tech Concentration is significantly larger for 
the latter.  
Table 4 presents the ten most prolific firms in our sample with respect to generating 
absolute numbers of breakthroughs.  It also adds five additional BT-prolific DBFs.  Merck and 
Roche are LDPFs with the largest and most diverse technology portfolios, being active in more 
than 60 technology classes (# IPC3). Although they each account for about 5.7% of all BTs in the 
sample,  these firms generate less BT compared to their technology size than Pfizer the most 
prolific in terms of absolute numbers of BTs generated in the sample.  Astra Zeneca, not among 
the biggest LDPFs in terms of technology size and scope,  is the most BT intense LDPF.   Eli Lilly,   
a large LDPF,  is not even in the top 10 for BTs.      
[INSERT TABLE 4 ABOUT HERE] 
DBFs are typically smaller in technology size and scope compared to LDPFs and as a 
consequence account for a lower absolute number of BTs.  But they are typically more 
breakthrough-intense,  i.e. hold a significantly higher share of breakthrough patents in their 
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portfolio than LDPFs (Share of Portfolio).15 Incyte is the DBF which generates the largest 
absolute number of BTs,  it also holds the largest technology size among DBFs.    
All this shows the large heterogeneity in BT performance both between and within 
LDPFs and DBF.  But Table 3 also shows an important heterogeneity within firms across 
technology areas,  motivating our analysis at the firm-technology level: firms typically only 
realize BTs in few of the technologies in which they are active (# IPC3 with BT-3 versus # IPC3).  
This holds particularly for LDPFs, less for the DBFs in Table 3. For example, Amgen and 
Millennium Pharma have the smallest scope among DBFs, but hold BTs in almost all sectors in 
which they are active. Finally, BTs tend to be concentrated in the core technology domains of 
the firm (see the final two columns in Table 4).        
5. Multivariate Analysis: Methods and Results 
5.1 Methods 
To explore the relationship between firms’ activities in a technological domain and the 
generation of breakthrough inventions in the domain we use discrete choice models, 
specifically logistic regressions, as our dependent variable is the likelihood of introducing 
breakthrough inventions by a focal firm in a focal technology in a focal year. We are mainly 
interested in establishing partial correlations between the probability of generating a highly-
cited patent in a given technology domain by a firm and a set of measures capturing the firms’ 
scientific activities. BTs are concentrated in a handful of technology domains in which firms 
operate, rendering count data models difficult to estimate because of over-dispersion. As the 
                                                          
15 Two-paired t-tests with unequal variance suggest that this difference is more striking the stricter is the criterion 
for breakthrough patents (the higher number of standard deviations to qualify for breakthroughs). 
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most salient facet of the analysis lays in the likelihood of having BTs rather than in the  number 
of breakthroughs,  we prefer a logistic analysis rather than count data models. Given the nature 
of our data, which is organized in three dimensions – firm, technology and year – we cluster 
standard errors at the technology-firm level to take into account dependence over time in the 
production of breakthrough inventions by firms in particular technologies. Finally, 25 
technology dummies and 6 year dummies are included. 
5.2 Results 
The regression results for the likelihood of generating high-impact innovations are 
reported in Table (5). The results for BT-3 are our benchmark and basic science intensities  at 
the firm and firm-technology level our major variables of interest.  
We find that basic science involvement at the firm-level matters for generating 
breakthrough inventions (Firm size intensity). Firms with a higher basic science intensity are 
more likely to produce breakthroughs: a change  in a firm’s science intensity (at the mean) is 
associated with an increase in the likelihood of generating breakthroughs. Furthermore, the 
coefficient is similar across BT definitions, suggesting similar impacts of science involvement on 
breakthroughs as we move toward more extreme definitions of the latter.  At the same time,  
firms’ involvement in basic science has no implications for the likelihood of having zero cited 
patents, suggesting that scientific involvement indeed improves the process of experimentation 
by increasing the odds of obtaining impactful outcomes.  
[INSERT TABLE 5 ABOUT HERE] 
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Yet, science involvement seems only to matter at the firm level for breakthroughs.  . 
Technology Science Intensity is not significantly associated with any measure of breakthroughs 
in the focal technology area. Technology Science Intensity is however significantly and 
negatively associated with the likelihood of generating inventions with no impact (zero forward 
citations), i.e. it helps to avoid zero impact inventions. The insignificance of the technology 
specific science involvement level for the likelihood of generating breakthroughs, coupled to 
the significance of the firm-level basic science variable is robust across alternative 
specifications.16 It suggests that the breakthrough rewards from science capacity are not 
reaped in the technology areas immediately implied in basic science,  but in other areas of the 
technology portfolio of the firm.  This is reminiscent of the role of basic science in supporting 
firms’ search strategies for breakthroughs by recombining new pieces of information with 
existing familiar ones.    
Technology size matters for breakthrough performance. Large technology firms (Firm 
tech size) are not only more likely to generate breakthroughs, but inventions of all kinds – from 
zero impact to the highest measured one. Once corrected for technology size,   being an SME 
no longer matters, suggesting it is technology size,  not employment size that matters for 
breakthrough performance. Given the technology size, the technology scope of firms (Tech 
Concentration), does not matter significantly for breakthrough performance.         
                                                          
16 We have also experimented with the inclusion of the share of publications in other technology fields than the 
focal one to the current specification and the substitution of Basic Science Intensity with the share of publications 
in other technology fields than the focal one. The results confirm the intuition that it is the involvement in science 
outside the focal technology which is associated with the generation of BTs. These additional results are available 
from the authors upon request. 
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To explain the within-firm heterogeneity in the likelihood of breakthrough generation 
across technologies,  both Tech Specialisation and  Tech Lead have a significant impact. Firms 
are more likely to generate breakthroughs in those technology areas where they hold a 
stronger technology lead over their competitors. Technology leaders in the field are also 
significantly more associated with zero cited patents. This is perhaps a reflection of a more 
defensive technology development strategy of incumbent leaders. At the same time, firms 
which are specialized in the focal technology, i.e. for which the focal technology is core in the 
firm’s overall technology portfolio,  are more likely to generate breakthrough inventions in the 
focal technologies, as the coefficient associated to Tech Specialization is always positive and 
statistically significant across the spectrum of BT  measures. Such firms are also more likely to 
generate zero cited inventions in the focal technology area. Once corrected for other firm and 
technology characteristics,  US firms are significantly less likely to generate BTs but also zero-
cited inventions.  Last, but not least,  although Biotech firms are generating less BTs in absolute 
terms, see section 4, the multivariate analysis, correcting for other firm and technology 
characteristics,  shows that Biotech firms are disproportionally more likely to generate BTs as 
compared to LDPFs.  This difference is sizeable and more pronounced for more extreme BTs.  
We might expect the difference in breakthrough performance between biotech firms 
and traditional pharmaceutical firms to permeate beyond a fixed effect, as the firm and 
firm/technology characteristics might play out differently for the two types of firms.  In Table 6 
and Table 7 we show the results of the split sample by type of firm: LDPFs (Pharma) and DBFs 
(Biotech). The split results indicate that the firm-level science effect (Firm Science Intensity) is 
homogeneous across firms’ typologies. Instead, the effect of Tech Science Intensity on avoiding 
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zero impact inventions  reported in the total sample is attributable to LDPFs only.  For DBFs 
there is no effect from technology-specific scientific activities.    
 [INSERT TABLE 6 ABOUT HERE] 
[INSERT TABLE 7 ABOUT HERE] 
What the split results also indicate is that DBFs which have a more concentrated 
technological portfolio generate more breakthroughs. The fact that this effect is only significant 
for DBFs might shed light on the different organization of the Biotech sector.  Among LDPFs,  
having a concentrated technology portfolio does not allow to stand out in terms of 
breakthrough performance.  It only helps to avoid failures as measured by zero-citation 
patents.    Whereas biotech firms are generally active in fewer technology fields than LDPFs,  
some tend to concentrate more than others on a limited set of technology classes (cf. Amgen 
versus Incyte or Genentech, see Table 3).  What the multivariate analysis shows is that these 
specializing DBFs are, all else equal, more likely to generate  BT inventions, compared to more 
diversified DBFs. But at the same time, and in contrast with LDPFs,   these specializing DBFs are 
also more likely to generate zero impact inventions.   These results would be consistent with 
specializing DBFs to be taken more risky research avenues.   The split analysis also shows that 
the significant inferior breakthrough performance of US firms, all else equal,   is mostly due to 
the LDPF subsample. In Biotech, US firms are not significantly underperforming with respect to 
breakthrough inventions. They are actually significantly better in avoiding zero impact 
inventions.    
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6. Conclusions 
This analysis contributes to the understanding of the processes generating breakthrough 
inventions in the pharmaceutical industry.  As opposed to previous studies, we take into 
account the within-firm heterogeneity of breakthrough performance by looking at the firm-
technology level.  We are particularly interested in the role of basic science in the generation of 
breakthrough inventions. We examine science involvement both at the level of the firm and the 
level of specific technologies. This allows us to check “where” the benefits of basic science are 
realized. We operationalize breakthroughs with varying levels of impacts. We distinguish 
dedicated biotech firms (DBFs) and large diversified pharmaceutical firms (LDPFs) in our 
analyses, comparing which determinants favour breakthroughs for each type of firm.    
We find that firms pursuing more intensively basic science, as measured by scientific 
publications authored by corporate researchers,  produce more breakthrough inventions. 
Surprisingly, breakthrough inventions are not associated with higher scientific efforts targeted 
to the focal technology. This insignificance at the technology specific science involvement level,  
coupled to the significance of the firm level suggests that the breakthrough rewards from 
science capacity are not reaped in the technology areas immediately involved in basic science,  
but in other areas of the technology portfolio of the firm. This result is consistent with the ideas 
advanced by Nelson (1959) in his seminal paper on the Economics of Basic Scientific Research, 
where he stated that advances in basic scientific knowledge very often have practical value in 
multiple technology fields. Gibb’s law of phases, for example, inspired the design of equipment 
in technologies as diverse as petroleum refining, rubber vulcanization, nitrogen fixation and 
metal-ore separation (Nelson, 1959, p. 302).   
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Our findings inform managerial practice on basic science. Our study shows that the 
effects of basic science are not reaped in their own technology classes,  but in other technology 
classes of the firm.  This justifies  assigning the responsibility for basic science at a central,  
corporate level. The role of central R&D departments is to complement the activities of 
decentralized R&D units by sponsoring R&D projects that are of strategic importance for the 
company as a whole (Du et al., 2013).  
Beyond science involvement, also firm’s scale, scope and specialisation across 
technologies matter for breakthrough performance. In line with previous findings, the overall 
technology size of the firm matters for predicting overall inventive performance, including 
breakthrough performance. Beyond size, technology scope only matters to differentiate among 
DBFs in breakthrough performance.  DBFs  with more concentrated technology portfolios are 
more likely to generate breakthroughs.  At the same time,  they are also more likely to generate 
zero impact patents, consistent with a higher risk strategy.  Firms are also more likely to 
generate breakthroughs in technology areas where they are specialized and hold a stronger 
technology lead over their competitors. After controlling for technology size and  differences in 
basic science and technology strategies, DBFs generate more breakthroughs than LDPFs. 
Our research has a number of limitations, which suggest directions for further research. 
In particular, one should be careful to generalize our findings to firms in other sectors.17  
Besides the measurement problem that arises in industries with a lower propensity to patent, a 
specific concern is that knowledge creation and recombination in the pharmaceutical industry 
                                                          
17 Further note that our sample consists only of firms with (relatively) high R&D expenditures. Our results may 
therefore be less representative for the population of very small DBFs in the pharmaceutical industry. 
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relies more on (basic) science than in other, less science-intensive industries (McMillan et al, 
2000;  Narin et al., 1997; Narin and Olivastro, 1992; Rosenberg, 1990). Not only the mere 
availability of a large base of public, codified knowledge that inventors can draw on, but also 
the specific challenges in integrating this external knowledge with firm-specific knowledge may 
be issues that play out differently in other industries. However, we suspect that our results do 
have relevance for firms in other industries in which science and technology development are 
closely linked, such as semiconductors and electronics (Pavitt, 1984; Klevorick et al, 1995). 
Consequently, it would be interesting to investigate whether the relations we have uncovered 
here hold up to scrutiny in non-science intensive industries. Further, we note as a caveat that 
we cannot fully rule out the possibility that the absence of a technology specific science effect 
might be partly caused by measurement errors in the science-technology concordance that is 
used for the creation of the basic science variables.  
We plan to extend the current research, with a distinct interest to further pin down the 
role of scientific advancements for breakthrough inventions in drug discovery.  Particularly the 
result of a firm level but no technology specific effect for science involvement discovered in the 
current analysis begs further investigation in which other than the focal technology areas firms 
can translate their scientific capabilities into breakthrough performance. This analysis would 
benefit from a more detailed level of technology analysis. Further research could also study 
which characteristics of basic science are amenable to breakthrough inventions. Do 
breakthrough inventions build only on radically new scientific insights, and how and how 
important are open, collaborative science modes to create breakthroughs?   Finally, we reckon 
as a fruitful approach for further research the consideration of alternative conceptualizations of 
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breakthroughs. More specifically, rather than using a simple count of a patent’s forward 
citations, its impact may be captured by the breadth of its influence on future inventions, e.g. 
across technology domains. In other words, a technological invention may constitute a 
breakthrough if it leads the way to substantial further progress in either a specific technological 
domain (“deepening”) or, as in the case of general purpose technologies, in a broad array of 
technologies (“widening”).  
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Tables  
Table 1: Variable Description 
VARIABLE  DESCRIPTION LEVEL* 
Zero 
Number of patents by the focal firm in the focal technology 
class that have NOT received any citations in the first 5 years 
after application at EPO FTY 
BT 3 
… that have received more citations than THREE standard 
deviation above the average number of citations in the first 5 
years after application at EPO FTY 
BT 4 
… that have received more citations than FOUR standard 
deviation above the average number of citations in the first 5 
years after application at EPO FTY 
BT 5 
… that have received more citations than FIVE standard 
deviation above the average number of citations in the first 5 
years after application at EPO FTY 
Firm Tech Size  Logarithm of the number of patent applications at EPO by the focal firm in year t-1 FY 
Tech Lead Share of patents in the focal technology by the focal firm at EPO in year t-1 FTY 
Tech Specialization Share of patents in the focal technology in the technological portfolio of focal firm in year t-1 FTY 
Tech Concentration 
Herfindahl Index of shares of technology classes in the 
technological portfolio of the focal firm calculated between t-4 
and t-1 FY 
 
Firm Science Intensity 
Number of scientific articles published by focal firm’s scientists 
between t-4 and t-1 divided by the number of patent 
applications between t-4 and t-1 FY 
Tech Science Intensity 
Number of publications relevant for the technology published 
by the focal firm’s scientists between t-4 and t-1 divided by the 
number of patent applications in the technology  between t-4 
and t-1 FTY 
US Dummy variable for US firms  F 
Biotech Dummy variable for Dedicated Biotech Firms (DBFs) F 
SME Dummy variables for firms with less than 250 employees FY 
F indicates that the variable is at the firm-level; FY indicates that the variable is at firm-year level; FTY indicates 
that the variable is firm-technology-year.
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Table 2: Summary statistics for breakthroughs  
  
All firms (3,080 obs) 
 
LDPF (1,648 obs) 
 
DBF (1,432 obs) 
 
Number of patents per firm/year/technology class mean % of total sd mean % of total mean % of total 
with 5-year fwd citations = 0 4.77 32% 11.31 6.81 33% 2.42 30% 
with 5-year fwd citations > mean + 3 sd (“BT 3”) 0.41 3% 1.23 0.49 2% 0.3 4% 
with 5-year fwd citations > mean + 4 sd (“BT 4”) 0.23 2% 0.79 0.27 1% 0.19 2% 
with 5-year fwd citations > mean + 5 sd (“BT 5”) 0.13 1% 0.51 0.14 1% 0.12 1% 
Total 14.71 100% 33.72 20.41 100% 8.14 100% 
T-tests on the differences of the means between LDPF and DBF are all statistically significant at the 1% level.   
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Table 2: Summary statistics for firm/technology characteristics  
  All Sample  LDPFs DBFs Difference1 
   Mean Std. Dev. Mean Std. Dev. Mean Std. Dev. 
Firm-Technology2        
Tech Lead 0.003 0.007 0.004 0.008 0.002 0.005 + *** 
Tech Specialization 0.222 0.187 0.192 0.205 0.256 0.157 - *** 
Tech Science Intensity 1.609 3.367 1.870 4.085 1.312 2.251 + *** 
Firm3        
Firm Tech Size 3.949 1.571 4.672 1.488 3.123 1.217 + *** 
Tech Concentration 0.328 0.128 0.332 0.132 0.323 0.122 + *** 
Firm Science Intensity 1.374 2.287 1.196 4.085 1.578 3.081 - *** 
US 0.449 0.497 0.330 0.470 0.583 0.493 - *** 
SME 0.216 0.441 0.066 0.248 0. 489 0.500  *** 
1 t-tests on the differences of the means of variables between LDPF and DBF. *** indicates statistical significance at the 1% level.  
2 Statistics for firm-technology level variables have been calculated from 3,080 observations (1648 for LDPFs and 1432 DBFs) 
3 Statistics for firm-level variables have been calculated from 136 observations (59 LDPFs and 80 DBFs) 
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Table 3: Summary statistics for firm/technology characteristics  
  
BT-3 Firm Tech Size 
Tech 
Lead 
Tech 
Specialization 
Tech 
Concentration 
Basic 
Science 
Intensity 
Tech 
Publication 
Share 
US Biotech SME 
BT-3 1    
      Firm Tech Size 0.325 1   
      Tech Lead 0.370 0.427 1  
      Tech Specialization 0.132 -0.508 -0.015 1 
      Tech Concentration -0.057 -0.334 -0.151 0.416 1 
     Basic Science Intensity 0.057 -0.130 -0.081 0.086 -0.011 1 
    Tech Publication Share 0.022 -0.565 -0.069 0.718 0.409 0.068 1 
   US 0.061 0.127 0.082 -0.043 -0.048 0.015 -0.049 1 
  Biotech -0.087 -0.489 -0.206 0.192 -0.047 0.103 0.212 0.292 1 
 SME -0.145 -0.488 -0.183 0.258 0.171 -0.015 0.289 0.016 0.431 1 
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Table 4: Distribution of Breakthroughs: Top 10 Firms & Largest Dedicated-Biotech Firms 
PARENT Type Patents BT-3 Share of Portfolio # IPC3 
# IPC3 
with BT-3 
Top-IPC3 
with most 
BT3 ** 
Share of 
Top-
IPC3 in 
Patent 
Portfolio 
Share of 
BT-3s in 
Top-
IPC3  
PFIZER LDPF 1619 50 3.09% 34 10 A61 86% 94% 
ASTRAZENECA LDPF 770 37 4.81% 24 6 A61 84% 100% 
MERCK CO LDPF 2429 36 1.48% 63 17 A61 66% 69% 
ROCHE LDPF 2207 36 1.63% 61 19 A61 57% 58% 
GLAXOSMITHKLINE LDPF 1126 30 2.66% 39 13 A61 84% 80% 
INCYTE CORPORATION DBF 555 29 5.23% 13 7 G01 62% 86% 
BRISTOL MYERS SQUIBB LDPF 931 28 3.01% 37 6 A61 86% 86% 
GENENTECH INC DBF 449 19 4.23% 14 6 A61 82% 26% 
HUMAN GENOME SCIENCES DBF 565 19 3.36% 10 8 A61 88% 63% 
WYETH LDPF 917 18 1.96% 20 5 A61 85% 78% 
VERTEX PHARMACEUTICALS DBF 177 14 7.91% 10 4 A61 81% 93% 
MILLENNIUM PHARMACEUTICALS DBF 399 13 3.26% 8 6 A61 66% 62% 
CHIRON DBF 393 12 3.05% 16 6 A61 80% 75% 
AMGEN DBF 251 7 2.79% 7 5 A61 91% 57% 
ELAN DBF 198 7 3.54% 16 4 A61 91% 71% 
Variable Description. Type: LDPF stands for Large Diversified Pharmaceutical Firm and DBF for Dedicated Biotech Firm; Patents: number of patent applications 
between 1995 and 2002; BT-3: Number of breakthrough patents with forward citations beyond three standard deviations from the technology average; Share 
of Portfolio: Share of BT-3 in firms’ patent portfolio; #-IPC3: Number of IPC-3 patent classes in which the focal firm applied for patents; # IPC3 with BT-3: 
Number of IPC3 in which the focal firm has breakthrough patents; Top-IPC3 with most BT3: IPC-3 where the focal firm has the majority of breakthroughs; 
Share of Top-IPC3 in Patent Portfolio: Number of patents in the IPC-3 with most BT-3 as share of all firm patents; Share of BT-3s in Top-IPC3: Number of BT-3 
in the IPC-3 with most BT-3, as share of all BT-3’s of the firm. 
**A61: Medical or Veterinary Science; C12: Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation Or Genetic Engineering; G01: 
Measuring; Testing  
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Table 5: Logit Estimations (All Firms: 3080 observations, 695 firm-technology clusters) 
  Dependent variable  = Likelihood of patents with 5-year forward citations in one of the following categories 
  0 > mean + 3 sd > mean + 4 sd > mean + 5 sd 
Firm Tech Size 0.922*** 1.053*** 1.050*** 1.194*** 
  (0.083) (0.088) (0.096) (0.114) 
Tech Lead 129.033** 86.883*** 105.586*** 57.590*** 
  (64.703) (21.33) (22.609) (17.085) 
Tech Specialization 2.326*** 2.757*** 2.128*** 2.805*** 
  (0.562) (0.577) (0.598) (0.739) 
Tech Concentration 0.039 0.894 1.409* 1.332 
  (0.509) (0.681) (0.777) (1.034) 
Firm Science Intensity 0.017 0.166*** 0.193*** 0.172*** 
  (0.019) (0.039) (0.046) (0.051) 
Tech Science Intensity -0.059*** -0.021 -0.041 -0.028 
  (0.021) (0.022) (0.036) (0.04) 
US -0.386*** -0.366** -0.295* -0.4** 
  (0.130) (0.143) (0.155) (0.168) 
Biotech 0.013 0.692*** 1.047*** 1.227*** 
  (0.159) (0.183) (0.201) (0.237) 
SME -0.239* -0.11 -0.247 -0.416 
  (0.140) (0.197) (0.233) (0.305) 
Intercept -3.529*** -8.868*** -9.262*** -10.385*** 
  (0.87) (0.874) (0.937) (1.078) 
YEAR DUMMIES YES YES YES YES 
TECHNOLOGY CLASS DUMMIES YES YES YES YES 
Pseudo R² 0.219 0.285 0.308 0.299 
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Table 6: Logit Estimations (Pharmaceutical Firms: 1648 observations, 355 firm-technology 
clusters) 
  Dependent variable  = Likelihood of patents with 5-year forward citations in one of the following categories 
  0 > mean + 3 sd > mean + 4 sd > mean + 5 sd 
Firm Tech Size 0.979*** 1.077*** 1.093*** 1.229*** 
  (0.130) (0.120) (0.122) (0.147) 
Tech Lead 86.152 75.709*** 86.887*** 32.363 
  (63.374) (26.10) (25.833) (20.319) 
Tech Specialization 2.049* 1.713 2.628** 3.424*** 
  (1.117) (1.070) (1.043) (1.31) 
Tech Concentration -2.418* 0.873 1.412 0.281 
  (0.995) (1.02) (1.233) (1.559) 
Firm Science Intensity -0.095 0.210*** 0.242*** 0.187** 
  (0.097) (0.069) (0.086) (0.089) 
Tech Science Intensity -0.067* -0.042 -0.083 -0.057 
  (0.035) (0.04) (0.058) (0.063) 
US -0.065 -0.652*** -0.518** -0.471** 
  (0.251) (0.193) (0.203) (0.207) 
SME -0.001 -0.707 -0.201 -0.021 
  (0.35) (0.446) (0.533) (0.667) 
Intercept -3.285*** -8.552*** -8.996*** -10.029*** 
  (0.975) (1.016) (1.047) (1.243) 
YEAR DUMMIES YES YES YES YES 
TECHNOLOGY CLASS DUMMIES YES YES YES YES 
Pseudo R² 0.249 0.325 0.328 0.301 
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Table 7: Logit Estimations (Biotechnology Firms: 1432 observations, 336 firm-technology 
clusters) 
  Dependent variable  = Likelihood of patents with 5-year forward citations in one of the following categories 
  0 > mean + 3 sd > mean + 4 sd > mean + 5 sd 
 Firm Tech Size 0.915*** 1.242*** 1.107*** 1.37*** 
   (0.097) (0.145) (0.16) (0.208) 
 Tech Lead 271.847*** 104.3031*** 155.387*** 107.372)*** 
   (90.346) (30.521) (34.082) (34.529) 
 Tech Specialization 1.951*** 1.6794** 0.127 0.739) 
   (0.655) (0.757) (0.866) (1.120) 
 Tech Concentration 1.822*** 2.4524*** 1.884* 3.467*** 
   (0.702) (0.888) (1.052) (1.285) 
 Firm Science Intensity 0.045 0.1307*** 0.159*** 0.185** 
   (0.029) (0.049) (0.058) (0.08) 
 Tech Science Intensity -0.015 0.0333 0.024) 0.051) 
   (0.037) (0.041) (0.061) (0.080) 
 US -0.476*** 0.0065 0.012 -0.3938 
   (0.163) (0.265) (0.310) (0.388) 
 SME -0.2387 0.2019 -0.098 -0.351 
   (0.158) (0.239) (0.267) (0.353) 
 Intercept -3.1816*** -8.2682*** -8.191*** -9.1284*** 
   (0.465) (0.731) (0.821) (0.944) 
 YEAR DUMMIES YES YES YES YES 
 TECHNOLOGY CLASS DUMMIES YES YES YES YES 
 Pseudo R² 0.189 0.278 0.313 0.331 
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